[
    [
        {
            "time": "2023-10-01",
            "original_text": "Americafirst Quantitative Funds Buys iShares 7-10 Year Treasury Bond ETF, iShares 10-20 Year ...",
            "features": {
                "keywords": [
                    "Americafirst",
                    "Quantitative Funds",
                    "Buys",
                    "iShares",
                    "Treasury Bond ETF"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "bonds"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Americafirst Quantitative Funds Buys iShares 7-10 Year Treasury Bond ETF, iShares 10-20 Year ...",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "10 Pharmaceutical Stocks to Buy According to Efrem Kamen’s Pura Vida Investments",
            "features": {
                "keywords": [
                    "Pharmaceutical Stocks",
                    "Buy",
                    "Efrem Kamen",
                    "Pura Vida Investments"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "10 Pharmaceutical Stocks to Buy According to Efrem Kamen’s Pura Vida Investments",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "SoftBank Vision Fund 2 Backs Cerebral at $4.8 Billion Valuation",
            "features": {
                "keywords": [
                    "SoftBank",
                    "Vision Fund 2",
                    "Backs",
                    "Cerebral",
                    "Valuation"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "SoftBank Vision Fund 2 Backs Cerebral at $4.8 Billion Valuation",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]